Oric Pharmaceuticals
Yahoo Finance • 28 days ago
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Sept. 05, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance,... Full story
Yahoo Finance • last month
ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Aug. 27, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance,... Full story
Yahoo Finance • 2 months ago
ORIC® Pharmaceuticals Expands Leadership Team with the Appointment of Kevin Brodbeck as Chief Technical Officer
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Aug. 18, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance,... Full story
Yahoo Finance • 3 months ago
Ladenburg Thalmann initiates ORIC Pharmaceuticals stock with Buy rating
Investing.com - Ladenburg Thalmann initiated coverage on ORIC Pharmaceuticals (NASDAQ:ORIC) with a Buy rating and a $15.00 price target on Tuesday. Currently trading at $10.65, the stock has significant upside potential, with analyst targe... Full story
Yahoo Finance • 3 months ago
Oric Pharmaceuticals director You Angie buys $262,898 in stock
Director You Angie of Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) recently purchased a total of $262,898 in company stock. According to a Form 4 filing with the Securities and Exchange Commission, the purchases were made in two transactions a... Full story
Yahoo Finance • 4 months ago
JPMorgan biotech/pharma analysts hold analyst/industry conference call
US SMid Biotech Analyst Rama and US Major & Specialty Pharmaceuticals Analyst Schott, along with Dr. Charles Ryan, Genitourinary Medical Oncologist at Memorial Sloan Kettering Cancer Center discuss the evolving treatment landscape in prost... Full story
Yahoo Finance • 4 months ago
Oric Pharmaceuticals files to sell 19.23M shares of common stock by selling shareholders
* Oric Pharmaceuticals (NASDAQ:ORIC [https://seekingalpha.com/symbol/ORIC]) filed a prospectus to resale 19.23M shares of common stock. * The company will not receive any proceeds from the sale of ordinary shares by the selling shareho... Full story
Yahoo Finance • 4 months ago
ORIC® Pharmaceuticals Announces $125 Million Private Placement Financing
Financing led by SR One and includes participation from new and existing investors, including Point72, Viking Global Investors, Venrock Healthcare Capital Partners, New Enterprise Associates (NEA), Nextech, Vivo Capital, and NEXTBio Capita... Full story
Yahoo Finance • 5 months ago
ORIC® Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Updates
Announced focused registrational clinical development plans for lead programs, extended cash runway, and accelerated/augmented corporate milestones Presented preclinical data supporting potential best-in-class profile of ORIC-944 in combi... Full story
Yahoo Finance • 6 months ago
Is ORIC Pharmaceuticals Inc. (NASDAQ:ORIC) the Best Biotech Penny Stock to Buy According to Hedge Funds?
We recently published a list of the 13 Best Biotech Penny Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where ORIC Pharmaceuticals Inc. (NASDAQ:ORIC) stands against other biotech penny stocks. Pet... Full story
Yahoo Finance • 6 months ago
ORIC® Pharmaceuticals Announces ORIC-944 Preclinical Presentation at the 2025 American Association for Cancer Research (AACR) Annual Meeting
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, March 25, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance... Full story
Yahoo Finance • 7 months ago
ORIC® Pharmaceuticals Announces Focused Registrational Clinical Development Plans for Lead Programs, Extended Cash Runway, and Updated Corporate Milestones
Anticipated registrational development plans for ORIC-944 and ORIC-114 prioritized to focus on indications with strongest clinical validation and highest unmet need ORIC-944 initiation of first Phase 3 trial in mCRPC expected in 1H 2026;... Full story
Yahoo Finance • 7 months ago
ORIC® Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Updates
Reported encouraging early safety and efficacy data in ongoing dose escalation trial for ORIC-944 in combination with androgen receptor inhibitors in patients with mCRPC Entered into clinical trial collaboration and supply agreement with... Full story
Yahoo Finance • 2 years ago
ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences
SOUTH SAN FRANCISCO and SAN DIEGO, Nov. 09, 2023 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today a... Full story
Yahoo Finance • 2 years ago
ORIC Pharmaceuticals Reports Third Quarter 2023 Financial Results and Operational Updates
Presented initial Phase 1b data for ORIC-114 in patients with EGFR and HER2 Exon 20 mutated NSCLC demonstrating potential best-in-class profile Initial Phase 1b data for ORIC-533 in patients with multiple myeloma to be presented at the 65... Full story
Yahoo Finance • 2 years ago
ORIC Pharmaceuticals to Present Initial Phase 1b Clinical Data for ORIC-533 in Multiple Myeloma at the 65th American Society of Hematology (ASH) Annual Meeting
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Nov. 02, 2023 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance,... Full story
Yahoo Finance • 2 years ago
Initial Phase 1 Dose Escalation Data of ORIC-114 in Patients with EGFR and HER2 Exon 20 Mutations Demonstrates Potential Best-In-Class Profile
CNS activity observed at multiple dose levels, including the first reported confirmed CNS complete response by an EGFR exon 20 inhibitor in a patient with documented untreated brain metastases Systemic responses observed at multiple dose... Full story
Yahoo Finance • 2 years ago
ORIC Pharmaceuticals to Present Initial Phase 1b Clinical Data for ORIC 114 in EGFR/HER2 Exon 20 Mutated NSCLC at the European Society of Medical Oncology (ESMO) Congress 2023
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Oct. 17, 2023 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance,... Full story
Yahoo Finance • 2 years ago
ORIC Pharmaceuticals to Participate in the 2023 Cantor Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Sept. 20, 2023 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance... Full story
Yahoo Finance • 2 years ago
Wall Street Analysts See Upside Potential for 10 Stocks with Rising Price Targets
In this article, we will discuss the 10 stocks whose price targets were recently raised by analysts. If you want to see more such stocks on the list, go directly to Wall Street Analysts See Upside Potential for 5 Stocks with Rising Price T... Full story
